CD339 antibody targets the CD339 antigen, also known as Jagged1. a cell surface protein belonging to the Notch ligand family. Jagged1 plays a critical role in the Notch signaling pathway, a highly conserved system regulating cell differentiation, proliferation, and apoptosis. It is expressed in various tissues, including endothelial, epithelial, and hematopoietic cells, and is involved in embryonic development, tissue homeostasis, and immune responses. Dysregulation of Jagged1-mediated Notch signaling has been implicated in cancers, cardiovascular diseases, and inflammatory disorders.
CD339 antibodies are widely used in research to study Notch pathway dynamics, particularly in tumor microenvironments where Jagged1 overexpression correlates with angiogenesis, metastasis, and drug resistance. These antibodies enable detection of Jagged1 expression via techniques like flow cytometry, immunohistochemistry, and Western blotting. Therapeutic applications are also emerging, with anti-Jagged1 antibodies explored for blocking Notch signaling in cancers (e.g., breast, leukemia) or modulating immune responses.
Developed as monoclonal or polyclonal reagents, CD339 antibodies vary in specificity, with some targeting extracellular domains for functional blocking or intracellular epitopes for signaling analysis. Validation remains essential due to pathway complexity and cross-reactivity risks. Overall, CD339 antibodies serve as vital tools for unraveling Jagged1's role in health and disease, bridging basic research and therapeutic innovation.